Mesoblast Ltd (ASX:MSB) Share Price

Company Profile

Business description
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
Contact
55 Collins Street
Level 38
MelbourneVIC3000
AUS
T: +61 396396036
E: [email protected]
https://www.mesoblast.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
73

Recommended

Morningstar analysts see value in several stocks under fire from shorts.

Lewis Jackson | 12 January 2022

Morningstar had forecast big losses for the drugmaker, which has been dropped from the ASX 200.

Emma Rapaport | 15 June 2020

The biotech giant has jumped 22pc a year for the past decade but new players are emerging.

Nicki Bourlioufas | 07 April 2019

Index	Last price	Change	% Change
All Ordinaries	9,140.50	11.00	0.12%
CAC 40	7,674.78	24.14	-0.31%
DAX 40	23,596.98	173.35	-0.73%
Dow JONES (US)	45,400.86	220.43	-0.48%
FTSE 100	9,208.21	8.66	-0.09%
HKSE	25,417.98	359.47	1.43%
NASDAQ	21,700.39	7.30	-0.03%
Nikkei 225	43,018.75	438.48	1.03%
NZX 50 Index	13,223.53	90.33	0.69%
S&P 500	6,481.50	20.58	-0.32%
S&P/ASX 200	8,871.20	8.60	0.10%
SSE Composite Index	3,812.51	46.64	1.24%